Browse > Article
http://dx.doi.org/10.25153/spkom.2017.21.2.013

Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with GMODT 100 mg/kg with 2.5 hr-intervals -  

Ryu, Eun-A (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University)
Kang, Su-Jin (Department of Preventive Medicine, College of Korean Medicine, Daegu Haany University)
Song, Chang-Hyun (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University)
Lee, Bong-Hyo (The Medical Research Center for Globalization of Herbal Medicine, College of Korean Medicine, Daegu Haany University)
Choi, Seong-Hun (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University)
Han, Chang-Hyun (Clinical Research Division, Korea Institute of Oriental Medicine)
Lee, Young-Joon (Department of Preventive Medicine, College of Korean Medicine, Daegu Haany University)
Ku, Sae-Kwang (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University)
Publication Information
Journal of Society of Preventive Korean Medicine / v.21, no.2, 2017 , pp. 127-137 More about this Journal
Abstract
Objectives : In our previous study, single co-administration GMODT within 5 min significantly inhibited the oral bioavailability of tamoxifen through variable influences on the absorption and excretion of tamoxifen. Therefore, the object of this study was to elucidate the possible effects on the pharmacokinetics of tamoxifen after single oral co-administration of GMODT with 2.5 hr-intervals. Methods : After 50 mg/kg of tamoxifen treatment, GMODT 100 mg/kg was administered with 2.5 hr-intervals. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of GMODT treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. PK parameters of tamoxifen (Tmax, Cmax, AUC, $t_{1/2}$ and $MRT_{inf}$) were analysis as compared with tamoxifen single administered rats. Results : Two-half hr-interval co-administration with GMODT induced variable changes on the plasma tamoxifen concentrations as compared with tamoxifen single treated rats, and especially significant (p<0.05) increases of plasma tamoxifen concentrations were demonstrated at 0.5 (199.61%) and 1 hr (101.06%) after end of co-administration with GMODT, and also related significant (p<0.05) decreases of $t_{1/2}$ (-39.54%) and $MRT_{inf}$ (-43.94%) as compared with tamoxifen single formula treated rats, at dosage levels of tamoxifen 50 mg/kg and GMODT 100 mg/kg with 2.5 hr-intervals, in this experiment. Conclusions : According to the results, GMODT critically decreased on the oral bioavailability of tamoxifen through variable influences on the absorption and excretion of tamoxifen. Hence, the co-administration of GMODT and tamoxifen should be avoided in the comprehensive and integrative medicine, combination therapy of tamoxifen with GMODT on the breast cancer.
Keywords
Gamiondam-tang; Pharmacokinetics; Drug-drug interactions; Rat; Tamoxifen; 2.5hr-intervals; $Nolvadex^{TM}$;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Desta Z, Ward BA, Soukhova NV, Flockhart DA, Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. The Journal of pharmacology and experimental therapeutics, 2004;310(3):1062-75.   DOI
2 Notley LM, Crewe KH, Taylor PJ, Lennard MS, Gillam EM, Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a,4-dihydroxy derivatives. Chemical research in toxicology, 2005;18(10):1611-8.   DOI
3 de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD, Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clinical pharmacokinetics, 2015;54(8):797-810.   DOI
4 Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM, Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer research, 1990;50(18):5851-7.
5 West CM, Reeves SJ, Brough W, Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. Cancer letters, 1990;55(2):159-63.   DOI
6 Reid AD, Horobin JM, Newman EL, Preece PE, Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast cancer research and treatment, 1992;22(2):153-6.   DOI
7 Dehal SS, Brodie AM, Kupfer D, The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. Drug metabolism and disposition: the biological fate of chemicals, 1999;27(3):389-94.
8 Lamberts SW, Verleun T, Hofland L, Oosterom R, Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. The Journal of clinical endocrinology and metabolism, 1986;63(6):1342-7.   DOI
9 Ritchie LD, Grant SM, Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. BMJ (Clinical research ed.), 1989;298(6682):1253.
10 Tenni P, Lalich DL, Byrne MJ, Life threatening interaction between tamoxifen and warfarin. BMJ (Clinical research ed.), 1989;298(6666):93.
11 Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, et al., Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999;5(9):2338-43.
12 Kwak MA, Park SJ, Park SH, Lee YJ, Ku SK, Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg within 5 min -. J Korean Med, 2016;37(2):1-11.   DOI
13 Park SJ, Kwak MA, Park SH, Lee YJ, Ku SK, Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated. J Soc Prev Korean Med, 2016;20(2):97-109.
14 Nakagawasai O, Yamadera F, Iwasaki K, Arai H, Taniguchi R, Tan-No K, et al., Effect of kami-untan-to on the impairment of learning and memory induced by thiaminedeficient feeding in mice. Neuroscience, 2004; 125(1):233-41.   DOI
15 Ryu E-A, Kang S-J, Song C-H, Lee B-H, Choi S-H, Han C-H, et al., Effect of (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats. J Korean Med, 2017;38(2):61-72.   DOI
16 Oh HK, Park SJ, Bae SG, Kim MJ, Jang JH, Ahn YJ, et al., Kami-ondam-tang, a traditional herbal prescription, attenuates the prepulse inhibition deficits and cognitive impairments induced by MK-801 in mice. Journal of ethnopharmacology, 2013;146(2):600-7.   DOI
17 Wang Q, Iwasaki K, Suzuki T, Arai H, Ikarashi Y, Yabe T, et al., Potentiation of brain acetylcholine neurons by Kami-Untan-To (KUT) in aged mice: implications for a possible antidementia drug. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2000;7(4):253-8.   DOI
18 Nakagawasai O, Yamadera F, Iwasaki K, Asao T, Tan-No K, Niijima F, et al., Preventive effect of kami-untan-to on performance in the forced swimming test in thiamine-deficient mice: relationship to functions of catecholaminergic neurons. Behavioural brain research, 2007;177(2):315-21.   DOI
19 Gibaldi M, Perrier D, Pharmacokinetics. 2nd ed. Taylor & Francis. 1982.
20 Bailer AJ, Testing for the equality of area under the curves when using destructive measurement techniques. Journal of pharmacokinetics and biopharmaceutics, 1988;16 (3):303-9.   DOI
21 Chiou WL, Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. Journal of pharmacokinetics and biopharmaceutics, 1978;6(6):539-46.   DOI
22 Adam HK, Gay MA, Moore RH, Measurement of tamoxifen in serum by thin-layer densitometry. The Journal of endocrinology, 1980; 84(1):35-42.   DOI
23 Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F, Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). Journal of steroid biochemistry, 1987;26(5):547-55.   DOI
24 Adam HK, Patterson JS, Kemp JV, Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer treatment reports, 1980;64(6-7):761-4.
25 Fabian C, Sternson L, Barnett M, Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer treatment reports, 1980;64(6-7):765-73.
26 Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA, Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer research, 1983;43(3):1446-50.
27 Jordan VC, Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast cancer research and treatment, 1982;2(2):123-38.   DOI
28 Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, et al., Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug metabolism and disposition: the biological fate of chemicals, 2007;35(11):2006-14.   DOI
29 AstraZeneca Pharmaceuticals, Nolvadex (tamoxifen citrate) prescribing information. 2003.
30 Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, et al., Osmotic bloodbrain barrier disruption chemotherapy for diffuse pontine gliomas. Journal of neurooncology, 2006;77(3):279-84.   DOI
31 Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, et al., Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation, 2005;111(5):650-6.   DOI
32 The BIG 1-98 Collaborative Group, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. The New England journal of medicine, 2009;361(8):766-76.   DOI
33 Jordan VC, Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. British journal of pharmacology, 1993;110(2):507-17.   DOI
34 Jordan VC, Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British journal of pharmacology, 2006;147 Suppl 1:S269-76.   DOI
35 Vehmanen L, Elomaa I, Blomqvist C, Saarto T, Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006;24(4):675-80.   DOI
36 Grilli S, Tamoxifen (TAM): the dispute goes on. Annali dell'Istituto superiore di sanita, 2006;42(2):170-3.
37 Osman KA, Osman MM, Ahmed MH, Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert opinion on drug safety, 2007;6(1):1-4.   DOI
38 Paganini-Hill A, Clark LJ, Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast cancer research and treatment, 2000;64(2):165-76.   DOI
39 Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ, Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage, 2004;21(1):364-71.   DOI
40 Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH, Effect of tamoxifen on sexual functioning in patients with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999;17(5):1488-92.   DOI
41 Rousset-Jablonski C, Thalabard JC, Gompel A, Tamoxifen contraindicated in women with hereditary angioedema? Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2009;20(7):1281-2.
42 Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, et al., Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast cancer research and treatment, 2006;100(3):273-84.   DOI
43 Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, et al., Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2008;23(8):1267-77.   DOI
44 Wilson SC, Knight PG, Cunningham FJ, Evidence for the involvement of central conversion of testosterone to oestradiol-17b in the regulation of luteinizing hormone secretion in the cockerel. The Journal of endocrinology, 1983;99(2):301-10.   DOI
45 Nalbandian G, Paharkova-Vatchkova V, Mao A, Nale S, Kovats S, The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. Journal of immunology (Baltimore, Md. : 1950), 2005;175(4):2666-75.   DOI
46 Berstein LM, Wang JP, Zheng H, Yue W, Conaway M, Santen RJ, Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004;10(4):1530-4.   DOI
47 Kim SY, Suzuki N, Santosh Laxmi YR, Rieger R, Shibutani S, a-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chemical research in toxicology, 2003;16(9):1138-44.   DOI